A5057249944- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Screening and Detection
- Lung Cancer Treatments and Mutations
- Fibroblast Growth Factor Research
- Esophageal Cancer Research and Treatment
- Colorectal and Anal Carcinomas
- Lymphoma Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Colorectal Cancer Surgical Treatments
- Radiomics and Machine Learning in Medical Imaging
- Eosinophilic Disorders and Syndromes
- Multiple and Secondary Primary Cancers
- Breast Cancer Treatment Studies
- Ethics in Clinical Research
- Asthma and respiratory diseases
- Gastrointestinal Tumor Research and Treatment
- Pancreatic and Hepatic Oncology Research
- Metastasis and carcinoma case studies
- Biomedical Ethics and Regulation
- Allergic Rhinitis and Sensitization
- Inhalation and Respiratory Drug Delivery
- Viral-associated cancers and disorders
Royal Marsden Hospital
2014-2024
Royal Marsden NHS Foundation Trust
2014-2023
Institute of Cancer Research
2004-2018
Institute of Cancer Research
2016
University of Padua
2016
Medical Research Council
2016
University College London
2016
University of Leeds
2016
Maastricht University
2016
Samsung Medical Center
2015
Mismatch repair (MMR) deficiency (MMRD) and microsatellite instability (MSI) are prognostic for survival in many cancers resistance to fluoropyrimidines early colon cancer. However, the effect of MMRD MSI curatively resected gastric cancer treated with perioperative chemotherapy is unknown.
Purpose The Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial established perioperative epirubicin, cisplatin, and fluorouracil chemotherapy as a standard of care for patients with resectable esophagogastric cancer. However, identification at risk relapse remains challenging. We evaluated whether pathologic response lymph node status after neoadjuvant are prognostic in treated the MAGIC trial. Materials Methods Pathologic regression was assessed resection...
FGFR1 and FGFR2 are amplified in many tumor types, yet what determines response to FGFR inhibition cancers is unknown. In a translational clinical trial, we show that gastric with high-level clonal amplification have high rate the selective inhibitor AZD4547, whereas subclonal or low-level did not respond. Using cell lines patient-derived xenograft models, initiates distinct oncogene addiction phenotype, characterized by FGFR2-mediated transactivation of alternative receptor kinases,...
Despite biomarker stratification, the anti-EGFR antibody cetuximab is only effective against a subgroup of colorectal cancers (CRCs). This genomic and transcriptomic analysis resistance landscape in 35 RAS wild-type CRCs identified associations NF1 non-canonical RAS/RAF aberrations with primary validated CRC subtypes as non-genetic predictors benefit. Sixty-four percent biopsies acquired harbored no genetic drivers. Most these had switched from cetuximab-sensitive subtype at baseline to...
Sequential profiling of plasma cell-free DNA (cfDNA) holds immense promise for early detection patient progression. However, how to exploit the predictive power cfDNA as a liquid biopsy in clinic remains unclear. RAS pathway aberrations can be tracked monitor resistance anti-EGFR monoclonal antibodies patients with metastatic colorectal cancer. In this prospective phase II clinical trial single-agent cetuximab
Recruitment to clinical trials can be challenging and slower than anticipated. This prospective patient survey aimed investigate the proportion of patients approached about a trial who agree participate, their motivations for participation views on aspects cancer research.Patients had been in any Gastrointestinal Lymphoma Unit at Royal Marsden were invited complete questionnaire. The statistical analysis is mainly descriptive, with percentages being reported. Univariate logistic regression...
The physician's global evaluation of treatment effectiveness (GETE) at 16 weeks has been shown to be the most effective assessment response omalizumab (XOLAIR®). This randomized, open-label, parallel-group study evaluated persistency responder classification in patients receiving added optimized asthma therapy (OAT).Patients (12-75 years, n = 400) with severe allergic asthma, uncontrolled despite Global Initiative for Asthma 2004 Step 4 therapy, received OAT and (n 272) or 128) 32 weeks....
<h3>Background</h3> Current guidelines recommend treatment with one or more long-acting bronchodilators for patients moderate severe chronic obstructive pulmonary disease (COPD). The authors investigated the approach of dual bronchodilation using indacaterol, a once-daily β<sub>2</sub> agonist, and muscarinic antagonist tiotropium, compared tiotropium alone. <h3>Methods</h3> In two identically designed, double-blind, 12-week studies, to COPD were randomised indacaterol 150 μg once daily...
Limited data exist regarding the correlation between MRI tumour regression grade (mrTRG) and pathological TRG (pTRG) in rectal cancer. mrTRG pTRG were compared cancer patients from two phase II trials (EXPERT EXPERT-C). The agreement radiologist pathologist was assessed with weighted κ test while Kaplan–Meier method used to estimate survival outcomes. One hundred ninety-one included. Median time completion of neoadjuvant treatment pre-operative surgery 4.1 weeks (interquartile range (IQR):...
To compare cisplatin plus fluorouracil (FU) versus carboplatin paclitaxel in chemotherapy-naïve advanced anal cancer to establish the optimal regimen.
Abstract Purpose: The steroid hormone 1,25-dihydroxyvitamin D3 is thought to protect against breast cancer. actions of are mediated via the vitamin D receptor (VDR), and a number polymorphisms in VDR gene have been identified. These result distinct genotypes, some which may alter susceptibility We investigated whether specific associated with cancer risk United Kingdom Caucasian population. Experimental Design: In retrospective case-control study, female patients (n = 398) control women 427)...
Insulin-like growth factor type 1 receptor (IGF-1R) mediates resistance to epidermal (EGFR) inhibition and may represent a therapeutic target. We conducted multicenter, randomized, double blind, phase II/III trial of dalotuzumab, an anti-IGF-1R monoclonal antibody, with standard therapy in chemo-refractory, KRAS wild-type metastatic colorectal cancer. Eligible patients were randomly assigned dalotuzumab 10mg/kg weekly (arm A), 7.5mg/kg every alternate week B), or placebo C) combination...
PATRIOT is a phase I study of the ATR inhibitor, AZD6738, as monotherapy, and in combination with palliative radiotherapy. Here, we describe protocol for this study, which opened 2014 currently recruiting comprises dose escalation both drug radiotherapy, expansion cohorts.
Outcomes with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) or CHOP-like chemotherapy in peripheral T-cell lymphoma are poor. We investigated whether the regimen of gemcitabine, cisplatin, methylprednisolone (GEM-P) was superior to as front-line therapy previously untreated patients.We did a phase 2, parallel-group, multicentre, open-label randomised trial 47 hospitals: 46 UK one Australia. Participants were patients aged 18 years older bulky (tumour mass diameter >10...
Abstract Background Circulating tumour DNA (ctDNA) to detect minimal residual disease (MRD) is emerging as a biomarker predict recurrence in patients with curatively treated early stage colorectal cancer (CRC). ctDNA risk stratifies guide adjuvant treatment decisions. We are conducting the UK’s first multi-centre, prospective, randomised study determine whether de-escalation strategy using chemotherapy (ACT) decisions non-inferior standard of care (SOC) chemotherapy, measured by 3-year free...
Abstract Purpose: The absence of postoperative circulating tumor DNA (ctDNA) identifies patients with resected colorectal cancer (CRC) low recurrence risk for adjuvant chemotherapy (ACT) de-escalation. Our study presents the largest CRC cohort to date tissue-free minimal residual disease (MRD) detection. Experimental Design: TRACC (tracking mutations in cell-free predict relapse early cancer) included stage I III resectable CRC. Prospective longitudinal plasma collection ctDNA occurred pre-...